CAMT entered this week carrying a 16% one-day loss, the biggest single-session selloff visible in the past year's earnings history. It closed May 12 at $174.63, down 11% on the week. What makes the setup worth examining is the divergence between that price action and what the Street did the very next morning: four firms raised their price targets in rapid succession.
The earnings print that triggered the drop was, on paper, a beat. Camtek posted Q1 numbers that topped the EPS estimate by $0.01. Revenue and profits surpassed consensus. But a guidance outlook that pointed to only modest year-on-year growth — with visibility extending into the first half of 2027 — appears to have disappointed a market that had priced in something more aggressive. The stock had run hard into the print, up roughly 48% year-to-date at the peak, trading above 45x forward earnings. When growth visibility came in cautious, the multiple reset fast.
The analysts who spoke up Wednesday morning were unanimous in direction. Oppenheimer raised its target to $195 while maintaining Outperform. Evercore ISI lifted to $200. Barclays moved to $185, and Needham went to $190 — all reiterated positive ratings. The lone holdout in tone is Morgan Stanley, which nudged its target a token $2 higher to $163 with an Equal-Weight rating that places it more than $20 below the analyst consensus mean of $185. That consensus now sits modestly above the current price, implying the Street collectively sees the selloff as an overshoot — though Stifel had already stepped to the sidelines in April with a downgrade to Hold at $185, a signal that valuation concern had been building even before the print. The EV/EBITDA multiple contracted sharply on the day, dropping roughly 10 turns to 40x, a meaningful compression even if the absolute level remains elevated for the sector.
Short positioning tells a story that predates the selloff. At 6.6% of the free float — or closer to 10.3% calculated against the tighter free-float base — this is a stock with a real short overhang, not incidental hedging. Short interest has actually been declining for weeks, falling 9% over the past month. The borrow market, while not alarmist, tightened into and through the earnings event: availability has been well below the normal range, with utilization touching 94.5% — its 52-week peak — on May 7, just days before the print. It has since eased fractionally to 91%. Cost to borrow has climbed about 22% over the past month to just under 2%, still modest in absolute terms but trending in the wrong direction for anyone carrying a fresh short. The ORTEX short score, at 70.5, places CAMT firmly in the elevated category and has remained broadly stable despite the week's move — suggesting the lending market is not signalling a capitulation by shorts.
Options positioning is less hedged than the price action might imply. The put/call ratio dropped to 0.64 on Tuesday, well below its 20-day average of 0.69, placing it 1.3 standard deviations on the bullish side. Calls are dominating open interest. Either options traders anticipated a quick recovery, or the protective demand simply didn't build ahead of what turned out to be a punishing print. With the stock now sitting roughly 16% off the earnings-day open, that call-heavy positioning describes residual paper loss rather than a hedge.
Among peers, the divergence is notable. NVMI fell 6% on the day and 4% on the week, tracking CAMT's direction in the inspection-tool space. ONTO was down nearly 9% on the week. By contrast AMAT and KLAC each gained roughly 5% over the same period — the larger-cap process equipment names demonstrating far more resilience, partly because their AI-capex exposure is more diversified and their valuations less demanding.
The ownership structure adds one more note of complexity. Parent Priortech holds 20.7% of shares and Chroma ATE controls a further 16.8%. Together, those two strategic holders effectively reduce the tradeable float to something well below the headline share count — which helps explain both the relatively tight availability in the borrow market and the velocity of the price move when conviction shifted. Insider data available in the system is stale (last trade dates to 2023), so no useful read can be drawn from that angle.
The next formal catalyst is Q2 earnings, scheduled for August 11. Between now and then, the debate is narrowly defined: whether the post-earnings de-rating is a one-time reset at a new, more rational multiple, or whether the guidance narrative — modest YoY growth, high AI revenue concentration, gross-margin pressure from smaller scale — continues to weigh. The analyst cluster of raises provides a near-term floor argument, but the gap between the Morgan Stanley target of $163 and the Evercore target of $200 illustrates how wide the range of credible outcomes remains.
See the live data behind this article on ORTEX.
Open CAMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
